PMC:7299399 / 8123-8666 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T44","span":{"begin":302,"end":310},"obj":"Disease"},{"id":"T45","span":{"begin":430,"end":446},"obj":"Disease"},{"id":"T46","span":{"begin":503,"end":511},"obj":"Disease"}],"attributes":[{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T81","span":{"begin":142,"end":143},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T82","span":{"begin":381,"end":384},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T35","span":{"begin":27,"end":36},"obj":"Chemical"},{"id":"T36","span":{"begin":233,"end":238},"obj":"Chemical"},{"id":"T37","span":{"begin":493,"end":498},"obj":"Chemical"}],"attributes":[{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T18","span":{"begin":430,"end":446},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T40","span":{"begin":0,"end":447},"obj":"Sentence"},{"id":"T41","span":{"begin":448,"end":543},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"165","span":{"begin":302,"end":312},"obj":"Species"},{"id":"166","span":{"begin":503,"end":513},"obj":"Species"},{"id":"167","span":{"begin":430,"end":446},"obj":"Disease"}],"attributes":[{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"Tax:2697049"},{"id":"A166","pred":"tao:has_database_id","subj":"166","obj":"Tax:2697049"},{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}

{"project":"2_test","denotations":[{"id":"32519842-32259480-158463","span":{"begin":121,"end":123},"obj":"32259480"},{"id":"32519842-32194980-158464","span":{"begin":536,"end":538},"obj":"32194980"}],"text":"The development process of antiviral therapies typically requires years before the therapies can be made widely available27 because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.28 Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs (29−31)."}